Skip to content

Public FDA record

Z-1022-2007: Zyoptix XP Epi Head, packaged 1 per container, Cat. #ZXP32040, packaged nonsterile and reuseable. Ophtha

Recall record Z-1022-2007 for Bausch & Lomb Inc. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-1022-2007
Company in FDA record
Bausch & Lomb Inc
FDA classification date
Aug 2, 2007
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 20, 2026
Recall classification
Unknown — no matched enforcement classification

Reason stated in the source

Reports have been received of stromal incursions after use of the product.

Source facts

Action
The firm notified their customers via telephone between 6/8-12/07. During the call, the customer was informed reports had been received of stromal incursions and they were to quit using the product and return it.
Initiated
2007-06-08
Root cause
Other
Terminated
2009-04-28
Distribution
Distribution was limited to "key" physicians in MN, SC, MD, and NJ. Foreign distribution was made to the firm's entities in The Netherlands, Singapore, Mexico, Canada, Hong Kong, and India.
Recall number
Z-1022-2007
Recall status
Terminated
CDRH record ID
53549
FDA classified
2007-08-02
Recall event number
38230

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗